Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. Hammond S, Meng X, Barber J, Mosedale M, et al. Toxicol Sci 2025;203:11-27.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hammond S, Meng X, Barber J, Mosedale M, et al. Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. Toxicol Sci 2025;203:11-27.
PMID: 39495155